Elliot Ehrich, MD
Home
About Us
Structure
Current Events
Past Events
Video Gallery
Policy & Reports
Awards
Media Coverage
Internship/Volunteers
Legal
Contact Us
 
 
Elliot Ehrich, MD
Venture Partner
5AM Ventures

Elliot Ehrich, M.D. joined 5AM Ventures in 2018 as a Venture Partner. Dr. Ehrich has spent over 25 years in drug development including the last eighteen years at Alkermes, plc, as Executive Vice President, R&D and Chief Medical Officer. While at Alkermes, he directed the development and successful FDA registration of VIVITROL and ARISTADA and partnered development of RISPERDAL CONSTA and BYDUREON. He established a drug discovery effort at Alkermes which has yielded a broad portfolio of proprietary drug development candidates in psychiatry, neurology, and immuno-oncology. Dr. Ehrich serves on the Scientific Advisory Boards of Praxis Precision Medicines, Aileron and Heptares and is a Strategic Advisor to Verge Genomics. Prior to Alkermes, Dr. Ehrich spent seven years at Merck & Co, Inc. working in clinical pharmacology and clinical development.

Dr. Ehrich received a B.A. degree from Princeton University and was a predoctoral fellow in molecular genetics at the European Molecular Biology Laboratory in Heidelberg, Germany. Following an M.D. degree at Columbia University, he completed a residency in internal medicine, subspecialty training in rheumatology, and a postdoctoral fellowship in immunology at Stanford University. Dr. Ehrich is based in the Boston, MA office.

© 2007 - USA India Chamber of Commerce Home | About us | Policy | Events | Photo Gallery | Awards | Media Coverage | Legal | Contact us